Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22   

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Avertissement: Cet article est reproduit à partir d'autres médias. Le but de la réimpression est de transmettre plus d'informations. Cela ne signifie pas que ce site Web est d'accord avec ses opinions et est responsable de son authenticité, et ne porte aucune responsabilité légale. Toutes les ressources de ce site sont collectées sur Internet. Le partage est uniquement destiné à l'apprentissage et à la référence de tous. En cas de violation du droit d'auteur ou de la propriété intellectuelle, merci de nous laisser un message.

LePlusRécent

  • "Select Shandong" Cloud Platform Austria's Leading Industry Cloud Roadshow Achieves Cooperation intention in Various Fields

    (Dazhongwang·Haibao News from Jinan) The "Select Shandong" Cloud Platform International Economic and Trade Cooperation Cloud Roadshow·Austria session was held on November 18th. With the theme of docking leading industries&sharing development opportunities, the event built a platform for economic and trade cooperation between Shandong and Austria to promote cooperation in the fields of ice and snow
  • 《问鼎全球高端 领创璀璨未来》​2021年引领全球各界巅峰人物——周和林

    周和林 1950年生于上海,祖籍浙江镇海。学生时代即习书法美术,1984年参加上海中国画院美术书法进修班,师承胡问遂,钱茂生等名师,曾获得“ 上海市职工书法篆刻展”一等奖,“神龙杯”全国青少年书法大赛园丁奖等。作品入编《上海书画家篆刻名典》,1984年由赵冷月,钱茂生介绍加入上海书法家协会,原为上海市少年宫,宜川学区艺术学校书法教师,现为上海东方书画院画师、中华卫视艺术风采栏目艺木会员、中国书画家联谊会新文艺群体书画家工作委员会委员、现在上海同欣进修学校书法兼职教师,民建会艺专委副主席.中国楹联书研会常务理事,新文艺报副编辑。
  • La Chine et le Brésil célèbrent la sortie de la chaîne de production du premier Monorail transocéanique au monde

    Shenzhen, Chine - Le 8 avril, BYD a franchi une nouvelle étape avec la sortie de la chaîne de production de son véhicule Bahia SkyRail à Shenzhen. Le Bahia SkyRail, situé dans la ville de Salvador, dans l'État de Bahia, au Brésil, est la première ligne Monorail au monde à être partiellement construite au-dessus de la mer.
  • DiDimessage "Burn After Reading", protégez votre vie privée

    À l'ère de l'information, l'information est un intérêt. L'Internet inclusif et ouvert, il faut l'admettre, a également apporté une série de risques de sécurité tels que la fuite d'informations et l'exposition de la vie privée, tout en réduisant la distance entre les personnes. En réponse à ce phénomène, DidiMessage est né.
  • DiDiMessage -- Un APP de chat crypté utilisé dans le monde entier

    Avec l'avènement de l'ère Internet, le problème de la vie privée préoccupe les gens depuis longtemps. Qu'il s'agisse des premières fuites de photos indécentes ou des fuites de données personnelles alarmantes d'aujourd'hui, les gens prêtent attention à leurs problèmes de vie privée à l'ère de l'Internet.
  • L'apport de la Chine en matière de lutte contre la pauvreté dans le monde

    ​Depuis le début de la réforme et de l'ouverture, plus de 770 millions de Chinois vivant en dessous du seuil de pauvreté sont sortis de la pauvreté, ce qui équivaut à plus de 70 % du total mondial sur la même période selon la norme internationale de pauvreté de la Banque mondiale, peut-on lire dans un livre blanc sur la réduction de la pauvreté.
  • The Undervalued Enterprise in the Shadow of Wikipedia, Quora, and MOOC

    Featuring websites such as Wikipedia, Quora, and MOOC, and their Chinese equivalents Baidu Baike (百度百科), Zhihu (知乎), and Dedao (得到), respectively, the online knowledge economy has spawned enterprises that make our lives more convenient.
  • Wang Wenzeng-Ambassadeur de l'image des Nations Unies dans le monde contemporain

    Accomplis à la fois dans la culture civile et militaire, la vertu et l'art deviennent nobles —— Un récit du célèbre calligraphe Wang Wenzeng
  • OMC decentralized insurance becomes the development direction of the industry

    The scale of global insurance market is developing rapidly. The global annual premium is more than 5 trillion US dollars, and it is still in rapid development. There is a hidden crisis behind the high growth data. The problem of trust system is always an insurmountable weakness of the traditional insurance industry, which has a serious impact on the sustainability of the insurance industry.
  • GOOD NEWS CONSORTIUM WILL BUILD THE TALLEST BUILDING IN TURKEY NAMED GOOD NEWS TOWER

    The Republic of Turkey was established in 1923. To commemorate the 100th anniversary of the founding of the nation in 2023, Turkish President Erdogan adopted various incentive policies to make Turkey one of the top ten economies in the world. In September 2018, the Turkish Parliament revised the bill to lower the minimum amount of real estate investment immigration from US$1 million to US$250,000,

Lien amical

Back to top
© Droits d'auteur 2009-2020 Paris au quotidien      Contactez nous   SiteMap